| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
LDC4297 is a novel and potent CDK7 (Cyclin-dependent protein kinase 7) inhibitor with IC50 of 0.13±0.06 nM for CDK7 and IC50s between 10 nM and 10,000 nM for all other analyzed CDKs. Cyclin-dependent protein kinase 7 (CDK7) regulates transcription and the cell cycle, two processes that are linked to viral replication in many different ways. LDC4297's affinity for CDK7 turns out to be incredibly high. LDC4297 inhibits HCMV replication in cultured primary human fibroblasts (HFFs) in a concentration-dependent manner, with an efficient 50% concentration (EC50) of 24.5 ± 1.3 nM. Interestingly, at submicromolar concentrations, CDK7 inhibition by LDC4297 is not linked to general cytotoxicity. In conclusion, the CDK7 inhibitor LDC4297 is a promising candidate for additional research into antiviral drugs, potentially providing fresh choices for an all-encompassing strategy of antiviral treatment.
| Targets |
CDK7 (IC50 = 0.13 nM); HSV-1 (IC50 = 0.02 μM); HSV-2 (IC50 = 0.27 μM)
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
LDC4297 is a newly developed and highly effective inhibitor of CDK7 (Cyclin-dependent protein kinase 7), with an IC50 of 0.13±0.06 nM for CDK7 and IC50s ranging from 10 nM to 10,000 nM for all other CDKs examined. Cyclin-dependent protein kinase 7 (CDK7) regulates transcription and the cell cycle, two processes that are linked to viral replication in many different ways. LDC4297's affinity for CDK7 turns out to be incredibly high. LDC4297 inhibits HCMV replication in cultured primary human fibroblasts (HFFs) in a concentration-dependent manner, with an efficient 50% concentration (EC50) of 24.5 ± 1.3 nM. Interestingly, at submicromolar concentrations, CDK7 inhibition by LDC4297 is not linked to general cytotoxicity. In conclusion, the CDK7 inhibitor LDC4297 is a promising candidate for additional research into antiviral drugs, potentially providing fresh choices for an all-encompassing strategy of antiviral treatment.
|
|
| Cell Assay |
Cultured cells seeded in 24-well plates are used for a trypan blue exclusion assay. The cells are incubated with increasing concentrations of antiviral compounds (ranging from 0.1 to 50 μM) for the indicated durations. After 10 minutes at room temperature and cell staining with 0.1% trypan blue, the percentage of viable cells is calculated by microscopic counting.
|
|
| Animal Protocol |
CD1 mice[1]
100 mg/kg Oral gavage; 100 mg/kg once |
|
| References | ||
| Additional Infomation |
LDC4297 is a pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an apoptosis inducer, an antineoplastic agent and an antiviral agent. It is a pyrazolotriazine, a member of pyrazoles, a member of piperidines, a secondary amino compound and an aromatic ether.
|
| Molecular Formula |
C23H28N8O
|
|
|---|---|---|
| Molecular Weight |
432.52
|
|
| Exact Mass |
432.239
|
|
| Elemental Analysis |
C, 63.87; H, 6.53; N, 25.91; O, 3.70
|
|
| CAS # |
1453834-21-3
|
|
| Related CAS # |
LDC4297 hydrochloride;2319747-14-1
|
|
| PubChem CID |
78161839
|
|
| Appearance |
White to off-white solid powder
|
|
| LogP |
3.578
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
594
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CC(C)C1=C(N2N=C1)N=C(OC3CNCCC3)N=C2NCC4=CC=CC=C4N5C=CC=N5
|
|
| InChi Key |
LSGRZENCFIIHNV-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H28N8O/c1-16(2)19-15-27-31-21(19)28-23(32-18-8-5-10-24-14-18)29-22(31)25-13-17-7-3-4-9-20(17)30-12-6-11-26-30/h3-4,6-7,9,11-12,15-16,18,24H,5,8,10,13-14H2,1-2H3,(H,25,28,29)
|
|
| Chemical Name |
2-piperidin-3-yloxy-8-propan-2-yl-N-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3120 mL | 11.5602 mL | 23.1203 mL | |
| 5 mM | 0.4624 mL | 2.3120 mL | 4.6241 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
